Skip to Main Content

Author Details

Shiaw-Yih Lin
The University of Texas MD Anderson Cancer Center
1996
100
42
PMIDPaper TitleJournal TitlePublished Year
38015043Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance.Mod Pathol2024
36924633A stability indicating LC-MS/MS method for quantification of a NOX Inhibitor R14 in its bisulfite adduct form for pharmacokinetic studies.J Pharm Biomed Anal2023
37909041Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins.Cell Rep Med2023
37907220Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway.J Immunother Cancer2023
37256648Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors.Clin Cancer Res2023
37449360Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.Clin Cancer Res2023
34653632Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.Ann Oncol2022
36359297Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer.Biomedicines2022
35926816Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.Ann Oncol2022
36253762Tumor microenvironment: barrier or opportunity towards effective cancer therapy.J Biomed Sci2022
35944232Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.JCO Clin Cancer Inform2022
35241495Spontaneous tumor regression following COVID-19 vaccination.J Immunother Cancer2022
35176131CNGPLD: case-control copy-number analysis using Gaussian process latent difference.Bioinformatics2022
35141022Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer.Am J Cancer Res2022
35110355Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.J Immunother Cancer2022
33172898Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.Clin Cancer Res2021
33736924High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.Ann Oncol2021
33636043Mechanisms of immunogenic cell death and immune checkpoint blockade therapy.Kaohsiung J Med Sci2021
34705519Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.Sci Transl Med2021
34066883A Gene Expression Signature to Predict Nucleotide Excision Repair Defects and Novel Therapeutic Approaches.Int J Mol Sci2021
34166757Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.Ann Oncol2021
33947685Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.Mol Cancer Ther2021
32109374Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer.Cancer Cell2020
32051231Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress.Mol Cancer Res2020
33294279Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer.Am J Cancer Res2020
32855206Integrated Genomic Characterization of the Human Immunome in Cancer.Cancer Res2020
32642299BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K.Am J Cancer Res2020
32612833Role of DNA repair defects in predicting immunotherapy response.Biomark Res2020
32358509PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.Nat Commun2020
30692636Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression.Oncogene2019
32577620The Tale of CHD4 in DNA Damage Response and Chemotherapeutic Response.J Cancer Res Cell Ther2019
30152517PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.Int J Cancer2019
31185210Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.Cancer Cell2019
31063534Corrigendum: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.Carcinogenesis2019
29533782BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.Cancer Cell2018
29888111CHD4 mutations promote endometrial cancer stemness by activating TGF-beta signaling.Am J Cancer Res2018
29615613Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers.Nat Commun2018
29632342Author Correction: Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation.Nat Cell Biol2018
29768207Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype.Cell Rep2018
27893709Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.Oncogene2017
28439535A murine preclinical syngeneic transplantation model for breast cancer precision medicine.Sci Adv2017
29097911MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer.Contrast Media Mol Imaging2017
29045845Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer.Cell Rep2017
28649435Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm.NPJ Syst Biol Appl2017
28566428Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers.Sci Transl Med2017
27164092Connecting the Dots: From DNA Damage and Repair to Aging.Int J Mol Sci2016
26546619mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.Clin Cancer Res2016
25362854Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model.Oncogene2015
29156836The role of Rak in the regulation of stability and function of BRCA1.Oncotarget2015
26468441New insights into tumor dormancy: Targeting DNA repair pathways.World J Clin Oncol2015
  • 1 - 50 of 100

Recommended Authors

Parasvi S Patel
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2016
Number of shared co-authors 0
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Samah El Ghamrasni
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2010
Number of shared co-authors 0
Jordi Carreras Puigvert
Department of Pharmaceutical Biosciences, Uppsala University
Career Start Year 2009
Number of shared co-authors 0
Georgia Velimezi
University of Patras
Career Start Year 2008
Number of shared co-authors 0
Srikanth Talluri
VA Boston Healthcare System
Career Start Year 2008
Number of shared co-authors 0
Silvano Piazza
International Centre for Genetic Engineering and Biotechnology
Career Start Year 2004
Number of shared co-authors 1
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Joanna I Loizou
Center for Cancer Research, Comprehensive Cancer Centre, Medical University of Vienna
Career Start Year 2002
Number of shared co-authors 0
Zhuo Chen
The First Hospital of Lanzhou University
Career Start Year 2002
Number of shared co-authors 0
Nuala McCabe
Queen's University Belfast
Career Start Year 2001
Number of shared co-authors 0
Tarek Abbas
University of Virginia
Career Start Year 2001
Number of shared co-authors 0
Junjie Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2000
Number of shared co-authors 11
Eddy S Yang
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 2
Dipanjan Chowdhury
Dana-Farber Cancer Institute
Career Start Year 1999
Number of shared co-authors 0
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 11
Thomas Helleday
The University of Sheffield
Career Start Year 1998
Number of shared co-authors 2
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 9
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 12
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 0
Christopher J Bakkenist
UPMC Hillman Cancer Center, University of Pittsburgh
Career Start Year 1994
Number of shared co-authors 2
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 8
James M Ford
Stanford University
Career Start Year 1989
Number of shared co-authors 3
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
Qimin Zhan
Peking University Cancer Hospital
Career Start Year 1989
Number of shared co-authors 0
Razqallah Hakem
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1987
Number of shared co-authors 1
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 4
Matthew Meyerson
Broad Institute
Career Start Year 1983
Number of shared co-authors 15
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 4
Ashok R Venkitaraman
University of Cambridge, Hutchison Research Centre
Career Start Year 1982
Number of shared co-authors 1

Collaborators

Daniel J McGrail
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Co-authored papers 29
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 18
Mien-Chie Hung
Co-authored papers 9
Yiling Lu
Co-authored papers 8
Nidhi Sahni
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
David J H Shih
University of Texas MD Anderson Cancer Center Houston
Co-authored papers 6
Zhenlin Ju
Co-authored papers 5
Yongsheng Li
Harbin Medical University
Co-authored papers 4
Amy B Heimberger
Northwestern University Feinberg School of Medicine
Co-authored papers 4
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 4
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Adel K El-Naggar
MD Anderson Cancer Center
Co-authored papers 3
Stephen J Elledge
Howard Hughes Medical Institute, Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 3
Song Yi
Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin
Co-authored papers 3
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Co-authored papers 3
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Co-authored papers 2
Christine B Peterson
University of Texas MD Anderson Cancer Center
Co-authored papers 2
Anil K Sood
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Lixia Diao
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Limei Hu
Aier Eye Hospital of Wuhan University
Co-authored papers 2
Jeannine Garnett
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Wei Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Wenjin Jim Zheng
University of Texas Health Science Center at Houston
Co-authored papers 2
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Xingzhi Song
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Neil E Bhola
Zai Lab (US) LLC
Co-authored papers 1
Rosemarie Schmandt
The University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center
Co-authored papers 1
Juan Xu
College of Bioinformatics Science and Technology, Harbin Medical University
Co-authored papers 1
Xu Hua
Institute for Cancer Genetics, Columbia University Irving Medical Center
Co-authored papers 1
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Release 1.2